Gadolinium Safety & Contrast Guidance

MRI

MHRA MRI Safety2021RCR BFCR(19)42019RCR iRefer2017, continuously updatedIR(ME)R 2017SI 2017/1322v2.0 · March 2026

Routine

EDInpatientOutpatient

GBCA Classification — Macrocyclic vs Linear

— ALL of the following must be met

Macrocyclic agents (gadobutrol, gadoteridol, gadoteric acid) are preferred — they have a more stable chelate structure and lower risk of free gadolinium releaseRCR BFCR(19)4
High-risk linear agents (gadodiamide, gadopentetate dimeglumine, gadoversetamide) were SUSPENDED by MHRA/EMA in February 2018 due to gadolinium deposition concernsMHRA MRI Safety
Linear agents with specific indications remain available: gadoxetate disodium (Primovist) for liver imaging; gadobenate dimeglumine (MultiHance) where macrocyclic agents are unsuitable
Standard dose: 0.1 mmol/kg body weight for most macrocyclic agents — use the minimum dose needed for diagnostic quality

— ALL of the following must be met

eGFR is required before gadolinium administration — this is mandatory, unlike iodinated contrast in emergency CT
eGFR ≥30 mL/min/1.73m²: standard macrocyclic gadolinium may be administered without additional precautions
eGFR 15–29 mL/min/1.73m²: use with caution — lowest effective dose of macrocyclic agent only, senior radiology review required, document risk–benefit discussionRCR BFCR(19)4
eGFR <15 mL/min/1.73m² or dialysis: avoid gadolinium unless absolutely essential — if administered, arrange dialysis within 2–3 hours; use macrocyclic agent only at lowest doseRCR BFCR(19)4
In acute kidney injury (AKI), eGFR may not reflect true renal function — treat as eGFR <15 unless recent stable baseline is known
eGFR should be measured within 3 months for stable outpatients; within 7 days for inpatients; on the day for acute/unstable patients

— ALL of the following must be met

NSF is a rare but serious fibrotic condition affecting skin, joints, and internal organs, occurring almost exclusively in patients with severe renal impairment (eGFR <15) exposed to GBCAs
Highest risk agents are the now-suspended high-risk linear GBCAs (gadodiamide, gadopentetate dimeglumine) — no confirmed unconfounded cases with macrocyclic agentsRCR BFCR(19)4
Risk factors: eGFR <15, dialysis, AKI, hepatorenal syndrome, perioperative liver transplant period, high or repeated GBCA doses
Prevention: check eGFR before all gadolinium administrations; use macrocyclic agents only; use lowest effective dose; avoid repeated doses within short intervals in at-risk patients
NSF incidence has fallen to near-zero since the suspension of high-risk linear agents and the adoption of macrocyclic-first policies

— ALL of the following must be met

Acute allergic-like reactions to GBCAs are rare (~0.004–0.7%) and are typically mild (urticaria, nausea); severe anaphylactoid reactions are very rare (~0.001–0.01%)
Previous mild reaction (isolated urticaria, nausea): may proceed with different GBCA agent; consider premedication with oral prednisolone 30 mg at 12 and 2 hours pre-scan and cetirizine 10 mg 1 hour pre-scan
Previous severe/anaphylactoid reaction: avoid gadolinium if possible — if essential, use a different agent class, premedicate, and ensure resuscitation facilities and trained staff are immediately available
Resuscitation equipment and trained personnel must be available in all areas where GBCAs are administered — follow local anaphylaxis protocol
All contrast reactions must be documented in the patient record, reported via local incident reporting, and the patient informed in writing with allergy alert updated

— ALL of the following must be met

Gadolinium deposition in the brain (dentate nucleus, globus pallidus) and bone has been demonstrated on post-mortem and imaging studies following repeated GBCA exposure, particularly with linear agents
No clinical symptoms or adverse outcomes have been definitively attributed to gadolinium deposition in patients with normal renal function — current evidence does not support clinical harm
MHRA/EMA position (current): the benefit–risk balance of macrocyclic GBCAs remains favourable; high-risk linear agents are suspended as a precautionary measure; continued monitoring is in placeMHRA MRI Safety
Minimise repeated gadolinium exposure: use the lowest effective dose, avoid unnecessary contrast-enhanced studies, consider unenhanced MRI sequences where diagnostic
Macrocyclic agents show significantly lower deposition than linear agents in both animal and human studies — this supports the macrocyclic-first policyRCR BFCR(19)4

— ALL of the following must be met

Avoid gadolinium in pregnancy unless the information is essential and cannot be obtained by other means — macrocyclic agents only if administeredRCR BFCR(19)4
Requires consultant radiologist approval with documented justification — see Pregnancy Imaging Guide for full details
Gadolinium and breastfeeding: safe to continue — less than 0.04% of maternal dose is excreted in breast milk; no interruption recommended
Cross-reference: see 'Pregnancy Imaging Guide' protocol for full pregnancy imaging guidance including CT, MRI, and contrast considerations

— ALL of the following must be met

Weight-based dosing: 0.1 mmol/kg for most macrocyclic agents — calculate and administer using an appropriate syringe/power injector with paediatric settings
Macrocyclic agents only in children — linear agents must not be used in the paediatric populationRCR BFCR(19)4
Neonates and infants: immature renal function increases NSF risk — use gadolinium only when essential, at the lowest effective dose, with consultant paediatric radiologist approval
eGFR calculation in children uses the Schwartz equation — adult eGFR formulae (CKD-EPI, MDRD) are not valid in paediatric patients

— ALL of the following must be met

Document the specific GBCA agent name, concentration, dose (mL and mmol/kg), and batch number in the patient record
Record the eGFR value and date of measurement — document justification if gadolinium is given with eGFR <30
Document any adverse reaction (including nil reaction for high-risk patients) — severity grading, treatment given, and outcome
For high-risk patients (eGFR <30, previous reaction, pregnancy), document informed consent discussion including risks and alternatives

Alert

High-risk linear gadolinium agents have been suspended since February 2018 — use macrocyclic agents only

Warning

eGFR must be checked before gadolinium administration — this requirement applies to all patients, unlike iodinated contrast in emergency CT

Information

eGFR ≥30: standard use; eGFR 15–29: caution with senior review; eGFR <15: avoid or arrange post-procedure dialysis

Warning

Gadolinium in pregnancy: avoid unless essential; macrocyclic only; consultant radiologist approval required

Information

Breastfeeding may continue without interruption after gadolinium contrast administration

Information

No confirmed cases of NSF with macrocyclic agents — risk is essentially confined to suspended linear agents in patients with eGFR <15

v2.02026-03-08New gadolinium safety cross-cutting guidance